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Background: BST-2 (bone marrow stromal cell antigen 2) is an interferon-inducible protein that inhibits virus
release by tethering viral particles to the cell surface. This antiviral activity of BST-2 is antagonized by HIV-1
accessory protein Vpu. Vpu physically interacts with BST-2 through their mutual transmembrane (TM) domains. In
this study, we utilized the BRET assay and molecular dynamics (MD) simulation method to further characterize the
interaction of BST-2 and Vpu.
Results: Amino acids I34, L37, P40 and L41 in the TM domain of BST-2, and L11, A18 and W22 in the TM domain of
Vpu were identified to be critical for the interaction between BST-2 and Vpu. The residues P40 in the TM domain of
BST-2 and L11 in the TM domain of Vpu were shown, for the first time, to be important for their interaction.
Furthermore, triple-amino-acid substitutions, 14–16 (AII to VAA) and 26–28 (IIE to AAA) in Vpu TM, not the
single-residue mutation, profoundly disrupted BST-2/Vpu interaction. The results of MD simulation revealed
significant conformational changes of the BST-2/Vpu complex as a result of mutating P40 of BST-2 and L11, 14–16
(AII to VAA) and 26–28 (IIE to AAA) of Vpu. In addition, disrupting the interaction between BST-2 and Vpu rendered
BST-2 resistant to Vpu antagonization.
Conclusions: Through use of the BRET assay, we identified novel key residues P40 in the TM domain of BST-2 and
L11 in the TM domain of Vpu that are important for their interaction. These results add new insights into the
molecular mechanism behind BST-2 antagonization by HIV-1 Vpu.
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Molecular dynamics simulationBackground
The bone marrow stromal antigen 2 (BST-2, also re-
ferred to as Tetherin, CD317 or HM1.24) blocks the re-
lease of human immunodeficiency virus type 1 (HIV-1)
by directly tethering viral particles to the membrane of
infected cells [1,2]. BST-2 is a type II integral membrane
glycoprotein of unusual topology. It comprises a short
N-terminal cytoplasmic tail (CT), followed by a single-
pass transmembrane domain (TM), a disulfide-linked
coiled-coil ectodomain (EC), and a C-terminal glycosyl-
phosphatidylinositol (GPI) component that acts as second* Correspondence: zdsys@vip.sina.com; guoafei@hotmail.com
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reproduction in any medium, provided the ormembrane anchor [3,4]. This unique membrane topology
suggests that BST-2 directly tethers budding virions to the
membrane of infected cells. Indeed, results of electron mi-
croscopy revealed that BST-2 is located between virus and
cell membranes as well as between tethered virions
[2,5-7]. Furthermore, BST-2 diminishes the infectivity of
released HIV-1 particles [8]. BST-2 has also been shown
to restrict viral release of other enveloped viruses, includ-
ing other retroviruses, filoviruses, arenaviruses, orthomy-
xoviruses, gamma-herpesviruses and rhabdoviruses [9-13].
These results suggest that BST-2 is a general cellular re-
striction factor for enveloped viruses.
HIV-1 viral protein U (Vpu) serves as a BST-2 antag-
onist [2]. Vpu is an 81-amino acid, oligomeric type I
trans-membrane protein encoded by an alternative open
reading frame in the env gene [14]. Vpu mediates thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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face, although the exact mechanism by which Vpu af-
fects the internalization, recycling, membrane transport,
or degradation of BST-2 requires further study [4]. Phos-
phorylation of a pair of conserved serine residues (S52
and S56) in the cytoplasmic tail of Vpu is required for
efficient Vpu-mediated degradation of BST-2 [15]. These
phosphorylated serines residues are recognized by an F-
box-containing ubiquitin ligase subunit, β-TrCP-2. Vpu
thus recruits the multisubunit SCF-β-TrCP E3 ubiquitin
ligase complex that causes ubiquitination and degrad-
ation of BST-2 [15-18]. Binding of Vpu to BST-2
through their transmembrane domains is crucial for the
antagonization [16,19-22]. NMR studies have shown that
BST-2 and Vpu directly contact between their trans-
membrane domains [16]. Studies have revealed that mu-
tation in the transmembrane of either BST-2 (L22, L23,
G25, I26, V30, I33, I34, I36, L37, L41, and T45) or Vpu
(A14, A18 and W22) renders BST-2 resistant to Vpu
[16,23-25].
Bioluminescence resonance energy transfer (BRET)
assay has been used for real-time monitoring of protein-
protein interactions in live cells [26]. The nonradiative
(dipole-dipole) transfer of energy from donor enzyme
to complementary acceptor fluorophore occurs after
substrate oxidation. Donor to acceptor energy transfer
and consequent emission from acceptor generally indi-
cates less than 10 nm of separation of the two proteins,
suggesting that the protein of interest are likely to be
interacting with each other (directly or as part of a
complex) [27]. Disruption or deficiency of interaction
between donor and acceptor proteins results in de-
creased donor to acceptor energy transfer. BRET has
been used to study a wide range of protein-protein inter-
actions in bacterial, plant and mammalian cells [28-30].
This technique has been previously utilized to study the
possible effects of small molecules on BST-2/Vpu inter-
action [31].
In this study, we utilized the BRET assay to identify
the amino acids in the TM regions of human BST-2 and
HIV-1 Vpu that are required for their interaction in live
cells. Several amino acids on each transmembrane do-
main were found crucial for the interaction of BST-2
and Vpu (BST-2: I34, L37, P40 and L41; Vpu: L11, A18
and W22). In addition to some of these interaction sites
that were reported in other studies [24,25], our data fur-
ther showed that P40 in the TM domain of BST-2 and
L11 in the TM domain of Vpu were also important for
this interaction. Furthermore, we observed that triple-
amino-acid mutants, 14–16 (AII to VAA) and 26–28
(IIE to AAA) in Vpu TM significantly affected the inter-
action, but not seen for single-residue mutation. The
novel residues of P40A of BST-2 and L11A, 14–16 (AII
to VAA) and 26–28 (IIE to AAA) of Vpu led to unstablecomplex compared to the wild-type (WT) as shown by
the results of molecular dynamics (MD) simulation. Fur-
ther studies showed that loss of interaction between the
two proteins directly affected the Vpu-mediated BST-2
degradation and the inhibition of viral release.
Results
Rluc-BST-2 and Vm-EYFP are suitable for BRET assay
BRET signal was generated using Rluc (Renilla lucifer-
ase) and EYFP (Enhanced Yellow Fluorescent Protein) in
this study. Rluc or EYFP was fused with human BST-2
or HIV-1 Vpu, respectively. In order to rule out the ef-
fect of BST-2 degradation by Vpu, the S52, 56A muta-
tion of Vpu was used in the BRET study (Figure 1a).
This is a degradation-null mutant but still interacts with
BST-2, and is hereafter referred to as Vm. Eight plasmids
were generated, namely Rluc-BST2 (R-B), EYFP-BST2
(E-B), BST2-Rluc (B-R), BST2-EYFP(B-E), Rluc-Vm(R-
Vm), EYFP-Vm(E-Vm), Vm-Rluc(Vm-R), Vm-EYFP(Vm-
E) (Figure 1b). Most of the fusion proteins were
expressed well in transfected HEK 293 T cells except for
B-E, B-R and Vm-R that had lower expression levels
(Figure 1c). Every pair of fusion proteins, containing
BST-2 and Vm fused with Rluc or EYFP, were co-
transfected into HEK293T cells. R-B and Vm-E pro-
duced BRET signal as strong as the positive control R-E
(Rluc fused with EYFP directly) (Figure 1d). We there-
fore used the R-B/Vm-E pair in the subsequent BRET
assay to study BST-2 and Vpu interaction (Figure 1e).
We next investigated the subcellular localization of the
wild-type and mutated proteins. The results in Figure 1f
revealed that R-B and Vm-E had localization similar to
wild-type proteins. R-B and Vm-E were expressed at
levels similar to the untagged, wild-type BST-2 and Vpu.
HIV-1 VLP release was inhibited by R-B. In addition, V-
E induced the degradation of R-B, and enhanced HIV-1
VLP release,while Vm-E neither degraded R-B nor res-
cued HIV-1 VLP release (Figure 1g).
Use BRET assay to monitor the interaction of BST-2 and
Vpu in live cells
In order to determine the specificity of the interaction
between BST-2 and Vpu, we substituted Vm with unre-
lated protein CD209 which is a type II transmembrane
protein consisting of C-terminal extracellular domain,
transmembrane region and N-terminal cytoplasmic re-
gion to perform BRET assay. The BRET signal was as
low as the negative control R/E (Figure 2a). We further
performed saturation and competition studies to validate
the specificity of the BRET assay [26]. HEK293T cells
were co-transfected with fixed amounts of plasmid ex-
pressing Rluc fusion protein R-B and increasing amounts
of plasmid expressing EYFP fusion protein Vm-E. The
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Figure 1 (See legend on next page.)
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Figure 1 BRET assay to monitor BST-2/Vpu interaction. (a) Western blot analysis of cellular lysates following the cotransfection of BST-2 and
Vpu or Vm plasmids into HEK 293 T cells. (b) Schematic representation of the plasmid DNA constructs. R-B and E-B were constructed with either
Rluc or EYFP fused to the N terminus of BST-2; B-R and B-E were constructed with either Rluc or EYFP fused to the C terminus of BST-2; The
N-terminus of Vm was fused with Rluc and EYFP to generate R-Vm and E-Vm; The C-terminus of Vpu was fused with Rluc and EYFP to engineer
Vm-R and Vm-E. (c) Expression of the fusion proteins. Western blot analysis of the cellular lysates following the transfection of the expressing
plasmid into HEK 293 T cells using anti-BST-2 and Vpu antibodies. (d) The BRET signals of BST-2 and Vpu interaction. HEK293T cells were
transfected with different combinations of donor and acceptor DNA constructs. The BRET ratio was measured using a Pekin Elmer reader
followed by the addition of substrate Coelenterazine at the final concentration of 5 μM. (e) The schematic diagram of the energy transfer
between R-B and V-E. (f) Subcellular localization of R-B and Vm-E. Immunofluorescence staining was performed to detect the localization of BST-2
(red), Vpu (green), R-B(red) and Vm-E(yellow) expressed in HEK 293 T cells. The nuclei were stained with DAPI (blue). Representative images are
shown. (g) Function analysis of the tagged BST-2 and Vpu proteins. Western blot analysis of the cellular lysates and the corresponding viral
lysates following cotransfection of the HIV-1 Gag-Pol construct (containing gag and pol genes) and other expressing plasmids into HEK293T cells
using anti-BST-2, anti-Vpu, anti-actin and anti-p24 antibodies.
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centrations of Vm-E. This phenomenon was not ob-
served in cells co-expressing E-CD209 protein and R-B
(Figure 2b). In addition, constant amounts of R-B and
Vm-E proteins were co-expressed with untagged Vm
that competed for interaction with the tagged protein












































Figure 2 The specificity of the BRET assay in detecting the interaction
BST-2 and Vpu. HEK293T cells were transfected with plasmid DNA and seed
using a Pekin Elmer reader. (b) The saturation curve of the BRET assay. HEK
and increasing dose of Vm-E or E-CD209 plasmid. The BRET ratio was detec
lysates was shown. (c) The competition curve of the BRET assay. HEK293T c
Vm-E and increasing dose of Vm or CD209 plasmid, and the BRET ratio wa
cellular lysates was shown.Increasing the amounts of untagged Vm diminished the
BRET ratio in a dose-dependent manner. Again, this
phenomenon was not observed in cells co-expressing
untagged protein CD209 that did not interact specifically
with R-B (Figure 2c). These results indicate that the
BRET assay is a useful and sensitive approach to study
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Figure 3 (See legend on next page.)
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Figure 3 The amino acids in TMD of human BST-2 responsible for HIV-1 Vpu interaction. (a) Mutation of the R-B TM domain. Every three
amino acids are mutated as a group. (b) HEK293T cells were cotransfected with Vm-E plasmid and R-B TM mutants, and the BRET ratio was
detected by using a Pekin Elmer reader. Western blot analysis of the cellular lysates was shown. (c) Mutation of R-B TM domain. (d) HEK293T cells
were cotransfected with Vm-E plasmid and a series of the R-B TM single amino acid mutants, and the BRET ratio was detected by using a Pekin
Elmer reader. Western blot analysis of the cellular lysates was shown.
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of human BST-2 and HIV-1 Vpu critical for their
interaction
Previous studies have demonstrated that the interaction
between human BST-2 and HIV-1 Vpu is mediated
through their TM domains [20,21]. Further detailed mu-
tagenesis studies revealed that multiple amino acid resi-
dues across the TM domains govern the interaction
between human BST-2 and HIV-1 Vpu [23-25]. In this
study, comprehensive mutagenesis and BRET assay were
performed to further identify residues in TM domains of
BST-2 and Vpu that are important for their interaction.
Plasmids encoding R-B mutants with triple-alanine
substitutions in TM domain of BST-2 (amino acids
22–48) were constructed. These mutants were expressed
at levels comparable to the wild type (Figure 3a and 3b).
We then transfected these mutants together with Vm-E
plasmid into HEK293T cells. Forty-eight hours post-
transfection, BRET assay was performed to determine
the interaction between R-B and Vm-E. The R-mB34-36,
R-mB37-39, R-mB40-42 mutants had significantly reduced
BRET signal compared to that of wild type R-B
(Figure 3b), indicating that the amino acids from pos-
ition 34 to 42 were crucial for BST-2 and Vpu inter-
action in live cells. Nine single-alanine-substituted mu
tants from position 34 to 42 were constructed to further
identify the key amino acids (Figure 3c). These nine mu-
tants were expressed at wild type levels (Figure 3d). Mu-
tation of residues I34, L37, P40 and L41 in TM domain
of BST-2 reduced BRET signals. A novel residue P40 was
shown for the first time being critical for BST-2 and
Vpu interaction.
In order to identify the residues in Vpu that are im-
portant for binding to BST-2, plasmids encoding Vm-E
mutants with triple-amino acid substitutions in TMD
of Vpu (amino acids 5–27) were constructed with
non-alanine to alanine residues and alanine to the same
hydrophobic valine residues (Figure 4a). All mutants
were expressed well in transfected HEK293T cells
(Figure 4b). Among the eight triple-amino acids-subs
tituted mutants, mVm11-13-E, mVm14-16-E, mVm17-19-E,
mVm20-22-E, mVm26-28-E had markedly reduced BRET
signal (Figure 4b). In order to determine the specific
amino acids responsible for the interaction between Vpu
and BST-2, each amino acid in Vm-E from positions 11
to 22 and 26 to 28 was mutated with non-alanine to ala-
nine residues and alanine to valine residues (Figure 4c).All mutants had the same expression levels compared
with Vm-E (Figure 4d). The mVm18-E and mVm22-E
mutants showed significantly decreased BRET ratio, and
mVm11-E mutant had decreased BRET ratio to a lesser
extent (Figure 4d). Unexpectedly, some triple substitu-
tions in the Vm TMD had significantly decreased BRET
signal, such as mVm14-16-E and mVm26-28-E, but none
of a single mutation of the three residues generated such
an effect.
Effect of TM mutations on BST-2/Vpu interaction by
molecular dynamics simulation
We further investigated how the mutants that were first
identified in our study affect the interaction between BST-
2 and Vpu by performing molecular dynamics (MD) simu-
lation. The simulation models were shown in Figure 5a.
Cluster analysis was also performed to generate the repre-
sentative complex structure of the largest family during
the simulation. For all the mutant complexes, the con-
formation of Vpu-TM fits to that of the WT complex very
well (Figure 5b). Thus, we aligned the representative struc-
ture of the mutant complex with the WTcomplex through
fitting the Vpu-TM structure, and the results are shown in
Figure 5c-f. Briefly, compared to the wild type (WT) com-
plex, the mutants showed less stable complexes which
were similar to previous simulation results of the complex
with I34, L37, or L41 in the TM domain of BST-2, as well
as A14, A18 or W22 in the TM domain of Vpu [32]. To
evaluate the overall conformational change of mutant
complexes, the fitting RMSD values were calculated for
each mutant complex through the alignment with the WT
complex. The RMSD values of P40A mutant at BST-2,
L11A mutant, 14–16 (AII to VAA) mutant, or 26–28 (IIE
to AAA) mutant at Vpu-TM are 1.94 Å, 1.52 Å, 0.85 Å, or
2.25 Å respectively, which means a close overall conform-
ation comparing to the WT complex. However, a destruc-
tion of helix at 38–41 position of BST2-TM was observed
for all mutants as a result of simulation. P40A mutant in
BST-2 (Figure 5c) or 26–28 (IIE to AAA) mutant in Vpu
(Figure 5f) cause more significant conformational change
than the other two mutants. Also, L11A mutant or 14–16
(AII to VAA) mutant in Vpu-TM destabilizes the helix
conformation of 23–25 motif in Vpu but reconstructs the
helix structure of 26–30 motif (Figure 5d, 5e). Thus,
marked local conformation changes are seen for all four
mutants, and such conformational changes likely disturb
the interaction between BST-2 and Vpu.
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Figure 4 (See legend on next page.)
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Figure 4 The amino acids in TMD of HIV-1 Vpu responsible for human BST-2 interaction. (a) Mutation of the Vm-E TM domain. Every three
amino acids were mutated as a group. (b) HEK293T cells were cotransfected with R-B plasmid and a series of Vm-E TM mutants, and the BRET
ratio was detected by using a Pekin Elmer reader. Western blot analysis of the cellular lysates was shown. (c) Mutation of the R-B TM domain.
(d) HEK293T cells were cotransfected with R-B plasmid and a series of Vm-E TM single amino acid mutants, and the BRET ratio was detected by
using a Pekin Elmer reader. Western blot analysis of the cellular lysates was shown.
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TM domains of human BST-2 and HIV-1 Vpu
To verify the functional role of the identified residues in
TM domain of BST-2, we tested these BST-2 mutants
for their sensitivity to Vpu. HEK293T cells were co-
transfected with HIV-1 Gag-Pol construct (containing
gag and pol genes) and Vpu together with a WT R-B or
R-B mutants. The virus-like particles (VLP) in the cul-
ture supernatants together with proteins expressed in
cell extract were assessed by Western blotting. As showna
WT





Figure 5 Structures of BST-2/Vpu complex determined by molecular d
cluster analysis, and the alignment of the mutant complexes (in ribbon, co
in green) with the wild-type complex (gray ribbons) was conducted in DS
mutants are highlighted by the black circles. (a) Description of the simulati
of the wild type (WT) BST-TM and Vpu-TM; (c) Effect of the P40A mutation
mutation in Vpu-TM on the BST-2 − Vpu interaction. (e) Effect of the 14–16
(f) Effect of the 26–28 (IIE to AAA) mutation in Vpu-TM on the BST-2 − Vpuin Figure 6a and 6c, the mutants the mutants R-mB34,
R-mB37, R-mB40 and R-mB41 became partially or com-
pletely resistant to Vpu antagonization. To determine
whether mutants resistant to Vpu antagonization are
also resistant to the degradation by Vpu, BST-2 in cellu-
lar lysates was examined by Western blotting. The re-
sults showed that R-mB34, R-mB37, R-mB40 and R-mB41
were not degraded by Vpu as much as wild type BST-2
(Figure 6a, 6b). In order to rule out the possible effect of
the Rluc sequence on the ability of BST-2 to inhibit virusBST P40A
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(c-f). The significant conformational changes between the WT and
on model in membrane; (b) Representative structures of the complex
in BST2-TM on the BST-2 − Vpu interaction. (d) Effect of the L11A
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Figure 6 (See legend on next page.)
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Figure 6 Functional validation of the crucial residues in the TMD of BST-2 for Vpu interaction. (a) Western blot analysis of the cellular
lysates and the corresponding viral lysates following the cotransfection of the HIV-1 Gag-Pol construct (containing gag and pol genes) and other
plasmids into HEK293T cells. (b) Relative BST-2 reduction was determined by densitometric scanning using the ImageJ program (NIH) aiming at
the specific bands. BST-2 level in cells that were cotransfected with R-B or R-B mutants and together with pcDNA was arbitrarily set as 100%. The
data shown was the average of three independent experiments. (c) Relative HIV-1 VLPs release was assessed by densitometric scanning using the
ImageJ program (NIH). The level of HIV-1 VLPs released from cells that were cotransfected of the HIV-1 Gag-Pol construct and R-B or R-B mutants
and together with pcDNA was arbitrarily set as 100%. The data shown was the average of three independent experiments.
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wild type BST-2 and observed similar results (Additional
file 1: Figure S1a). These data provided direct evidence
that I34, L37, P40 and L41 of human BST-2 determine
Vpu susceptibility in addition to Vpu interaction. The
loss of interaction between the two proteins directly af-
fected the subsequent BST-2 degradation and the inhib-
ition of viral release (Figure 6a, 6c).
To further characterize the function of the residues in
Vpu TMD, a series of Vpu TM crucial mutants were
constructed containing the wild type S52 and S56 resi-
dues. HEK293T cells were cotransfected with HIV-1
Gag-Pol construct and BST-2 together with a series of
key amino acid substituted V-E TM mutants. The VLP
in the culture supernatants together with proteins
expressed in cell extract were determined by Western
blotting. The results showed that mutants mV11-E,
mV18-E, mV22-E partially lost their ability to promote
HIV-1 VLP release (Figure 7a, 7c). In the meantime,
mV11-E, mV18-E, mV22-E were unable to degrade BST-2
(Figure 7a, 7b). We also tested the above Vpu mutations
by inserting them into the wild type Vpu and observed
similar results (Additional file 1: Figure S1b). These re-
sults indicated that the L11, A18 and W22 residues in
Vpu TM domain are essential for Vpu to counteract hu-
man BST-2 (Figure 7a, 7c).
Discussion
BRET signal is a ratio of the EYFP long wave emission
(530 nm) divided by the Rluc short wave emission
(475 nm) [27]. The BRET based assay was for the first
time used by Kuhl et al. to monitor BST-2/Vpu inter-
action with the aim to study the effect of small mole-
cules in this regard [31]. A similar flow cytometry-based
FRET assay was used by Schildler et al. to identify novel
protein interaction partners in a high-throughput format
[33]. Here we used BRET assay to identify the crucial
amino acids in TM of the two proteins. In our study,
Vm (S52, 56A mutant) were utilized instead of wild type
Vpu because Vpu degrades BST-2 and this will compli-
cate the study of Vpu/BST-2 interaction. After testing
different combinations of fusion proteins in BRET assay,
we selected the group of BST-2 fused with Rluc at
N-terminal and Vm fused with EYFP at C-terminal. Pre-
vious studies showed that tagging human BST-2 at N-terminus and tagging Vpu at C-terminus do not inter-
fere with their function and cellular localization [24].
This technique allowed us to successfully identify four
amino acid residues in human BST-2 TM (I34, L37, P40
and L41) and three amino acid residues in Vpu TM
(L11, A18 and W22) that are required for their inter-
action. Findings with I34, L37 and L41 in BST-2 TM
and A14, A18 and W22 in Vpu TM were reported by
other groups [24,25]. However, the other two sites, P40
in BST-2 TM and L11 in Vpu TM were shown for the
first time in this study as the critical determinants for
Vpu/BST-2 interaction. It was reported that P40A muta-
tion abolished susceptibility to Vpu without affecting the
interaction of BST-2 and Vpu [24]. In contrast, our re-
sults showed that the P40A mutation affected this inter-
action to the same degree as I34A in our BRET assay.
This discrepancy was likely due to the different ap-
proaches that were used to characterize BST-2 and Vpu
interaction. As opposed to the BRET assay that we used,
the BiFC method was employed in their study to moni-
tor BST2 and Vpu interaction. In addition, a recent
study based on cyteine cross-linking support the inter-
action between BST-2 P40C and Vpu A7C [34]. In
addition, we replaced alanine in Vpu TM with valine
and did not observe the effects of A14L and A14F as
previously reported, but the A18V effect is in line with
that shown for A18L and A18F [25,35]. However, the
triple-amino-acids substitution of 14–16 (AII to VAA)
produced significantly decreased BRET ratio. The same
result was also seen in the triple-amino-acids substitu-
tion of 26–28 (IIE to AAA). Namely, substitution of
multiple amino acids, but not a single residue mutation,
significantly affects the interaction. It was reported that
deletion of residues I15, I16 and I17 or deletion of I26
and I27 in Vpu TM potently block the physical inter-
action between human BST-2 and Vpu, and prevent
Vpu from enhancing HIV-1 virus release [36]. These re-
sults indicated that multiple isoleucine in HIV-1 Vpu
TM play an important role in forming the hydrophobic
interaction surface between the two proteins. Different
from other reports, we observed that L11 in Vpu TM
also contributes to the interaction between the two pro-
teins albeit to a lesser extent.
In summary, results of our BRET assays identified
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Figure 7 (See legend on next page.)
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Figure 7 Functional validation of the crucial residues in the TMD of Vpu for BST-2 interaction. (a) Western blot analysis of the cellular
lysates and the corresponding viral lysates following the cotransfection of the HIV-1 Gag-Pol construct (containing gag and pol genes) and other
expressing plasmids into HEK293T cells. (b) Relative BST-2 reduction was determined by densitometric scanning using the ImageJ program (NIH).
BST-2 level in cells that were cotransfected with HIV-1 Gag-Pol, R-B and pcDNA was arbitrarily set as 100%. The data shown were the average of
three independent experiments. (c) Relative HIV-1 VLPs release was assessed by densitometric scanning using the ImageJ program (NIH). The
level of HIV-1 VLPs released from cells that were transfected with HIV-1 Gag-Pol, R-B and V-E was arbitrarily set as 100%. The data shown were the
average of three independent experiments.
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Mutations P40A in BST-2 and L11A, 14–16 (AII to
VAA) and 26–28 (IIE to AAA) were first shown in our
study to interfere with the interaction of Vpu and BST-
2. Results of molecular dynamics simulation further
support this observation. Compared to the wild type
complexes, the mutant complexes are less stable and
show local conformation changes including the loss of
helical structure and the formation of new helix. Such
conformational changes possibly lead to the weakened
interaction between BST-2 and Vpu. Further studies
showed that the identified key residues in the TM do-
mains of human BST-2 and HIV-1 Vpu were important
for their respective functions. The loss of interaction
between the two proteins directly affected the Vpu-
mediated BST-2 degradation and the BST-2 inhibition
of viral release.
BST-2/Vpu interaction has been used as the target to
identify small molecules that antagonize HIV-1 Vpu
function by cell-based ELISA monitoring the up-
regulation of cell surface BST-2 [37]. BRET assay is
simple, rapid, non-invasive, and is suitable for develop-
ing a new high-throughput screening assay. The scree-
ning assay based on BRET method can lead to
discovery of small molecules that disrupt the inter-
action between BST-2 and Vpu and rescue the antiviral
activity of BST-2.
Conclusions
In this study, we utilized the BRET assay to further de-
fine the interaction of BST-2 and Vpu, and identified
novel residues P40 in the TM domain of BST-2 and
L11 in the TM domain of Vpu that were important for
their interaction. Furthermore, triple-amino-acid sub-
stitutions, 14–16 (AII to VAA) and 26–28 (IIE to
AAA) in Vpu TM, not single-residue mutation, exerted
significant effect on BST2/Vpu interaction. The signifi-
cant conformational changes of the BST2-Vpu com-
plex structure caused by mutating P40 of BST-2 and
L11, 14–16 (AII to VAA) and 26–28 (IIE to AAA) of
Vpu were demonstrated by molecular dynamics (MD)
simulation. In addition, disrupting interaction between
the two proteins directly affected the subsequent BST-
2 degradation and the inhibition of viral release. Theseresults add new insights into the molecular mechanism
behind BST-2 antagonization by HIV-1 Vpu.
Methods
Plasmids construction
The human BST-2 (hBST-2) and HIV-1 Vpu cDNA
were gifts from Chen Liang (Lady Davis Institute for
Medical Research, McGill University). pR-B, pE-B, pB-
R, pB-E, pR-Vm, pE-Vm, pVm-R were generated by
subcloning Renilla luciferase or EYFP cDNA and hu-
man BST-2 or Vpu cDNA into the pcDNA™3.1/V5-His
A vector (Invitrogen). pVm-E was generated by sub-
cloning codon optimization Vm cDNA into pEYFP-N1
(Invitrogen). A series of BST-2 and Vpu TM mutants
were generated by overlapping PCR-based mutagenesis.
pE-CD209 was generated by subcloning EYFP cDNA
and CD209 cDNA into the pcDNA™3.1/V5-His A vec-
tor (Invitrogen). All constructs were verified by nucleo-
tide sequencing. The Vpu, hBST-2 and p24 antisera
were obtained from the NIH AIDS Research and Refer-
ence Reagent Program. PEI (408727) was purchased
from Sigma. Coelenterazine h was purchased from
Promega.
Cell culture and transfection
Human embryonic kidney (HEK293T, ATCC #CRL-
11268) cells were cultured in complete DMEM (Gibco)
supplemented with 10% fetal calf serum (FCS), penicillin
(100 U/ml), and streptomycin (100 μg/ml). 8 × 105 cells/
well was seeded in 6-well plates one day prior to trans-
fection. Cells were transfected with various plasmids de-
pending on the experiment, using PEI (Sigma) according
to the manufacturer's protocol.
Immunofluorescence staining and confocal microscopy
For immunostaining, cells on coverslips were transf-
ected as described above and then fixed in 4% parafor-
maldehyde. After two washes in 1× phosphate buffered
saline, the cells were permeabilized with 0.5% Triton
X-100. Staining was performed with primary antibodies
including Rabbit BST-2 antiserum (1:1,000 dilution)
and Vpu (1:1,000 dilution). Anti-rabbit FITC-conju-
gated or TRITC-conjugated antibodies (1:500 dilution)
were used as secondary antibodies. Images were
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microscope (Leica Microsystems).
BRET assay
HEK293T cells were seeded in six-well plates (8 × 105 cells
per well) 24 hours prior to transfection. Plasmids were
transfected using PEI (Sigma) according to the manufac-
turer’s instructions. Forty-eight hours after transfection,
cells were washed twice and detached into 1 ml 1× phos-
phate buffered saline, and then distributed into 96-well
microplates at 1 × 105 cells per well (Corning 3600). The
substrate coelenterazine h (Promega) was added at a final
concentration of 5 μM. Readings at 475 nm (reflecting the
bioluminescence given off by Rluc) and 530 nm (reflecting
the resonance energy transfer from Rluc to EYFP) were
measured simultaneously by a Perkin Elmer instrument.
The BRET ratio was calculated as emission at 530 nm
(light emitted by EYFP)/emission at 475 nm (light emitted
by Rluc). The BRET ratios reported were corrected by
subtracting the ratios obtained in cells expressing the
donor only (Rluc).
Viral isolation
To produce viruses, cells were seeded in 10-cm dishes
(5 × 106 cells per dish) 24 hours prior to transfection.
The HIV-1 Gag-Pol construct (containing gag and pol
genes) and other plasmids were transfected using PEI
(Sigma) according to the manufacturer’s instructions.
Forty-eight hours after transfection, the culture superna-
tants were filtered through a 0.45 μm filter, and virus
particles were pelleted by ultracentrifugation through a
20% sucrose cushion at 35,000 rpm for 1 hour at 4°C
using a Beckman SW 41Ti rotor.
Western blotting
Cells or viruses were lysed in RIPA buffer (0.1% SDS, 1%
Triton X-100, 1% sodium deoxycholate, 150 mM NaCl,
10 mM Tris [pH 7.5], 1 mM EDTA), and equal amounts
of cell or viral lysate were separated by SDS-PAGE on a
12% gel, followed by transferring proteins onto nitrocel-
lulose membranes (Gelman Science). The membranes
were probed with BST-2 antiserum (1:2,000 dilution),
anti-Vpu serum (1:5,000 dilution), anti-p24 antibody
(1:5,000 dilution), or a mouse monoclonal antibody
against actin (1:5,000 dilution), followed by incubation
with IRDye™ secondary antibodies (1:20,000). Protein
bands were visualized with an LI-COR Odyssey instru-
ment and quantified using the Image J automated digit-
izing program (NIH).
Construction of initial model and MD simulations of BST-
2 TM and Vpu TM complex
The initial complex structures for BST-2 TMD peptide
and Vpu TMD peptide were generated using DiscoveryStudio 2.5 based the previous reported WT complex.
The initial structures were embedded into an explicit
DOPC lipid membrane including explicit solvent using
Discovery Studio 2.5 to generate the input structures for
the later molecular dynamic simulation in membrane.
The membrane was generated using the VMD soft suit
(25), following by the 3 ns pre-equilibrium in AMBER
(University of California, San Francisco). The partial
charges on DOPC monomer were calculated by fully re-
producible ab-initio electronic structure computations
with Gaussian 09 (Gaussian, Inc., Wallingford CT) using
Hartree-Fock self consistent field (HF-SCF) with 6-31G*
basis set after optimizing with DFT-B3LYP and succes-
sively with HF-SCF at 6-31G* level. The partial charges
were then extracted following RESP protocol with
ANTECHAMBER program of the AMBER suite. MD
simulations were performed using the AMBER10 pack-
age, all-atom parm94 force fields, particle mesh-Ewald
summation, SHAKE algorithm, and a time-step of 2 fs.
The systems were minimized using the steepest decent
method, followed by the conjugate gradient method to
remove the bad contacts. An equilibrium period of
120 ps was performed before the MD simulations com-
menced. The 10 ns long MD simulations were con
ducted in the NPT ensemble at 310 K. After the simula-
tion was completed, a cluster analysis was performed for
the snapshots taken from the period of 3–9 ns, which
amounts to 6000 snapshots for each simulation. Con-
formation clustering was performed with a radius of 2 Å
using the “Kclust” module implemented in the MMTSB
software suite (The Scripps Research Institute). The
obtained representative structure of the largest cluster
family would be served as the representative conform-
ation for the corresponding complex.Additional files
Additional file 1: Figure S1. Functional validation of the crucial
residues in the TMD of BST-2 and Vpu for their interaction (a) Crucial
residues in the TMD of BST-2 for Vpu interaction. Upper panel: Western
blot analysis of the cellular lysates and the corresponding viral lysates
following the cotransfection of the HIV-1 Gag-Pol construct and other
plasmids into HEK293T cells. Middle panel: Relative BST-2 reduction was
determined by densitometric scanning using the ImageJ program (NIH)
aiming at the specific bands. BST-2 level in cells that were cotransfected
with BST-2 or BST-2 mutants and together with pcDNA was arbitrarily set
as 100%. Lower Panel: Relative HIV-1 VLPs release was assessed by
densitometric scanning using the ImageJ program (NIH). The level of HIV-
1 VLPs released from cells that were cotransfected of the HIV-1 Gag-Pol
construct and BST-2 or BST-2 mutants and together with pcDNA was
arbitrarily set as 100%. (b) Crucial residues in the TMD of Vpu for BST-2
interaction. Upper panel: Western blot analysis of the cellular lysates and
the corresponding viral lysates following the cotransfection of the HIV-1
Gag-Pol construct and other expressing plasmids into HEK293T cells.
Middle panel: Relative BST-2 reduction was determined by densitometric
scanning using the ImageJ program (NIH). BST-2 level in cells that were
cotransfected with HIV-1 Gag-Pol, BST-2 and pcDNA was arbitrarily set as
100%. Lower Panel: Relative HIV-1 VLPs release was assessed by
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http://www.retrovirology.com/content/10/1/84densitometric scanning using the ImageJ program (NIH). The level of HIV-
1 VLPs released from cells that were transfected with HIV-1 Gag-Pol and
pcDNA was arbitrarily set as 100%. In both middle and lower panels of
(a) and (b), the data shown were the average of three independent
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